Clinical Trial Update: Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating inhaled AP-301 for primary graft dysfunction after lung transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Dysfunction After Lung Transplantation

Drugs mentioned

• AP-301 (AP-301)

Snippet

Sponsor: Apeptico Forschung und Entwicklung GmbH | Conditions: PGD Primary Graft Dysfunction | Phase 2 | Status: COMPLETED